Answers are grounded in this paper and cite their sources.
This research assesses serum irisin levels and biochemical parameters in AMI patients, revealing significant differences compared to healthy controls.
Acute myocardial infarction (AMI) is themostcommon form of cardiovascular disease (CVD), that leads to death. Myocardial infarction might directly increase irisin secretion through damaged cardiomyocytes. This study investigated the role of serum irisin level in myocardial infarction patients compared to control and explored its correlation with myocardial infarction in human patients. Sixty patients with acute myocardial infarction and 60 healthy control subjects were comprised in this study. Irisin level was measured using the ELISA method. The mean age of AMI patients was 61.30, 62.38, and 59.21 years for STEMI, NSTEMI, and control, respectively. The ratio of males and females with AMI was 2:1.6, where 37 (61.6%) and 23 (39.4%) were male and female, respectively. The mean irisin levels were 69.83, 72.63and 204.8 ng/ml for STEMI, NSTEMI, and control groups, respectively. In conclusion, this study approved a significant decrease in the level of the irisin AMI patients group in comparison to the healthy control group.
No takes yet. Share an insight, caveat, or question.
Oliwi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: